January 31, 2025

AbbVie Surges 8% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate

business people have a meeting about company statistics

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.

OK